Changes in NO activity may play an important role in the early increase in microvascular flow that has been implicated in the pathogenesis of diabetic microangiopathy. We assessed, in the in situ spinotrapezius muscle preparation of 6 weeks' streptozotocin-diabetic rats (n=6) and of agematched controls (n 8), basal inside diameters of A2-A4 arterioles and the reactivity to topically applied acelcholine and nitroprusside, before and after NG-nitro-L-arginine. In diabetic rats, cholinergic vasodilatation in A2-A4 arterioles was intact. Basal diameter in A3 and A4 arterioles was significantly higher in streptozotocin-diabetic rats.
INTRODUCTION
Microangiopathy has a major impact on morbidity and mortality of patients with diabetes mellitus. [1] An important hypothesis regarding the pathophysiology of diabetic microangiopathy is the hemodynamic hypothesis, 21 which states that an early, reversible increase in microvascular flow eventually leads to an endothelial injury response and microvascular sclerosis. [2] [3] [4] Using a mathematical model and experimental data on nitric oxide (NO) production and degradation rates, Vaughn et al., showed that the range of NO action may exhibit significant spatial heterogeneity in vivo and that the microcirculation is the optimal site for NO to exert its regulatory function. 5, 61 An increased flow early in diabetes, possibly as a result of enhanced NO production, has been described in several microvascular beds. +31 20 4440629/4440531, Fax: +31 20 4440502, e-mail: cda.stehouwer@azvu.nl 221 addressed only overall changes in flow. In order to gain insight in the exact role of NO in microangiopathy, it is necessary to assess its activity and effectivity at different sites of the microcirculation, as several orders of arterioles can react differently to chemical and mechanical vasoactive stimuli. [9] [10] [11] Recently, it was shown that the small arterioles that control capillary perfusion are capable of responding differently in a spatially organised way and that metabolic changes are able to change this pattern of diameter change. [12] The earliest changes in the microvasculature caused by the metabolic disturbance in type 1 diabetes can most likely be observed in striated muscle, which is metabolically the most active tissue. Indeed, changes in reactions in different orders of arterioles of striated muscle to several vasoactive substances have been observed in rats 6 weeks after the induction of diabetes by streptozotocin (STZ). [13] To gain more insight regarding the Classification of the vessels [20, 21] is also illustrated in Figure 1 10-4mol/L, i.e., a dose high enough to cause maximal dilatation in control animals, as established in pilot experiments). Finally, adenosine (Ad), a mainly endothelium-independent vasodilator was added. [23] [24] [25] The dose of Ad to obtain maximal dilatation was previously assessed at 10-4mol/L; the diameter after application of this dose was considered as the passive diameter and this diameter was set at 100%. This approach enabled us to relate basal diameters and the effects of the different drugs to a diameter that was independent from the initial contractile state. [26] After this series, we added L-NNA (10 -4 Table I . At the day of the experiment, after an overnight fast, the glucose levels of both the DM and control rats had been [15, 27] Using intravital microscopy, we found an increase in basal diameter in A3 and A4, but not in A2 arterioles after 6 weeks of STZ-induced diabetes mellitus (Fig. 2) . There was a greater change in diameter after L-NNA in the diabetic rats as compared to the control rats, especially in A3 arterioles (Fig. 3) . This suggests that the increase in basal diameter observed in diabetic rats is at least partially due to an increased contribution of endogenous NO to basal diameter in the A3 arterioles. Although NO production was increased significantly in A3 arterioles only, it cannot be excluded that also in A2 and A4
arterioles there was some increase in NO production in diabetic rats. These findings support the hypothesis of Williamson et al. , that an increased NO production occurs in the early phase of DM. I2sl An increased NO production was also observed in the kidney of STZ rats. [29] HOWever, several studies also report weaker relaxation responses to endothelium-dependentagents after induction of diabetes with STZ. [30] [31] [32] [33] These differences might be explained by variations in experimental set-up, the type of endothelium-dependent relaxation response that was investigated, the type of vessel, the duration of diabetes and differences in the elevation in glucose levels that were obtained in STZ rats.
Although NO has been indicated as an antiatherosclerotic molecule, [34, 35] [42] In this study we investigated changes in arteriolar reactivity after 6 weeks of STZ induced diabetes. We found an increased basal diameter in A3 and A4 arterioles and an unchanged diameter in A2 arterioles. This would be expected to result in a decreased pressure gradient from A2 arterioles to precapillary arterioles and thus in an elevated capillary pressure, which indeed has been observed in patients with type 1 diabetes mellitus. [43] There are several possible causes for the changes in arteriolar reactivity in streptozotocin diabetes. Firstly, moderate hyperglycemia can cause changes in oxidative stress and increased production of reactive glycation products. Both for acute and chronic hyperglycemia it has been shown that hyperglycemia increases NO production and decreases the bioavailability of NO. [44"45] Secondly, changes in arteriolar reactivity might be primarily due to the decreased delivery of nutrients to the muscle cells, causing an autoregulatory dysfunction leading to vasodilatation. I2-41 Thirdly, streptozotocin-induced diabetes causes marked atrophy of hindlimb skeletal muscles, which is accompanied by a relative increase in flow capacity per tissue mass. [46] It cannot be excluded that the changes in arteriolar reactivity that 
